San Francisco, 22 July 2025: The Report Mixed Mode Chromatography Resin Market Size, Share & Trends Analysis Report By Technique (Ion Exchange-Hydrophobic, Hydroxyapatite), By End-use (Pharmaceutical & Biotechnology), By Region, And Segment Forecasts, 2025 - 2030

The global mixed mode chromatography resin market size is expected to reach USD 223.9 million by 2030, registering a CAGR of 12.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growing number of contract manufacturing organizations (CMOs) and contract research organizations (CROs), along with increasing use of chromatography resin in separation of monoclonal antibodies, is anticipated to propel the market.

The Ion exchange - Hydrophobic resin segment is expected to dominate the global market till 2025. Demand for this technique is attributed to growth in drug discovery by pharmaceutical companies.

These companies use chromatography techniques to separate complex mixtures and purification of materials. Increasing number of epidemic diseases such as Zika and Ebola is expected to further boost the mixed mode chromatography resin market.

Asia Pacific, especially China and India, is expected to generate significant demand for mixed mode chromatography resin owing to growing pharmaceutical sector, coupled with abundance of high skilled workforce and increase in disposable income.

Presence of global pharmaceutical and biotechnology companies, along with their research and development facilities, has enabled North America to be a key market for mixed mode chromatography resin. Massive healthcare expenditure is also driving the expansion of the market in this region.

Request sample report of Mixed Mode Chromatography Resin Market@ https://www.grandviewresearch.com/industry-analysis/mixed-mode-chromatography-resin-market/request/rs1

This growth is attributed to the increasing demand for biopharmaceuticals, particularly monoclonal antibodies and vaccines, necessitating efficient purification techniques to ensure high product purity and yield. In addition, the rise of single-use technologies in bioprocessing enhances operational efficiency and reduces costs.

The expansion of Contract Manufacturing Organizations (CMOs) seeking effective purification solutions further propels market growth. Moreover, ongoing advancements in chromatography resin technology improve performance and scalability, meeting the evolving needs of the industry.

The mixed-mode chromatography resin incorporates ligands with both hydrophobic and ionic characteristics, allowing it to interact with biomolecules based on their charge, hydrophobicity, and size. This capability enhances the purification processes for proteins, peptides, and nucleic acids, increasing selectivity and flexibility in separating complex mixtures. As the demand for biopharmaceuticals rises, particularly for monoclonal antibodies, vaccines, and recombinant proteins, companies seek efficient purification methods to ensure high product purity and yield.

In addition, monoclonal antibody production, crucial for therapeutic applications, particularly benefits from the effectiveness of mixed-mode chromatography resins in achieving desired purity levels and adopting single-use technologies in bioprocessing facilities, further propelling the market. These technologies integrate seamlessly with mixed-mode chromatography resins, streamlining operations while reducing costs. In monoclonal antibody production, single-use systems significantly cut setup times and eliminate the need for cleaning validations, thus enhancing overall efficiency. Furthermore, expanding Contract Manufacturing Organizations (CMOs) in the biopharmaceutical sector presents new opportunities for resin suppliers.